![]() ![]() ![]() He advocates for more economic support and for the need of a “structural link between pharma industry and hospitals”. ![]() Dr Lázaro believes that ”more education on entrepreneurship at research centres is needed” as well as “the creation of specific innovation units to help researchers in this new and sometimes frightening world”. The group filed a patent in 2008 and today is working to launch the drug to the market. Dr Tejedor discovered that a compound called Cilastatin could help prevent and treat acute renal failure, “still an unmet medical need”, says Dr Alberto Lázaro, the researcher in Tejedor’s team that is now leading the project. Telara Pharmaceuticals was born thanks to the long years of research done by Dr Alberto Tejedor, former Director of the Nephrology Department at Hospital Universitario Gregorio Marañón, who sadly passed away from Covid-19 last May. He believes that there is a lack of entrepreneurship culture in healthcare and that “more funding and stability is needed in order to execute your projects”. Pérez-Rodríguez says the “encouragement” they had from the Madrid Health Service ( SERMAS) was key to “transform into a private entity the research we had been doing for years”. The team has developed a technological infrastructure to measure and prevent frailty, fruit from a project from the Geriatrics Department at the hospital. One of the spin-off that will be in place very soon is POSITIVE, created by Dr Leocadio Rodríguez-Mañas and researcher Rodrigo Pérez-Rodríguez, both working at the Biomedical Research Foundation of Hospital Universitario de Getafe. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |